Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes

L Pleyer; S Burgstaller; R Stauder; M Girschikofsky; W Linkesch; M Pfeilstocker; EM Autzinger; C Tinchon; T Sliwa; A Lang; WR Sperr; D Geissler; P Krippl; D Voskova; DH Rossmann; K Schlick; J Thaler; B Halter; S Machherndl-Spandl; G Theiler; P Valent; O Eckmullner; Richard Greil

Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes

L Pleyer, S Burgstaller, R Stauder, M Girschikofsky, W Linkesch, M Pfeilstocker, EM Autzinger, C Tinchon, T Sliwa, A Lang, WR Sperr, D Geissler, P Krippl, D Voskova, DH Rossmann, K Schlick, J Thaler, B Halter, S Machherndl-Spandl, G TheilerP Valent, O Eckmullner, Richard Greil

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Journal	BLOOD
Volume	124
Issue number	21
Publication status	Published - 2014
Event	56th Annual Meeting of the American-Society-of-Hematology - San Francisco, CA Duration: 6 Dec 2014 → 9 Dec 2014

Cite this

Pleyer, L., Burgstaller, S., Stauder, R., Girschikofsky, M., Linkesch, W., Pfeilstocker, M., Autzinger, EM., Tinchon, C., Sliwa, T., Lang, A., Sperr, WR., Geissler, D., Krippl, P., Voskova, D., Rossmann, DH., Schlick, K., Thaler, J., Halter, B., Machherndl-Spandl, S., ... Greil, R. (2014). Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. BLOOD , 124(21).

Pleyer, L ; Burgstaller, S ; Stauder, R et al. / Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. In: BLOOD 2014 ; Vol. 124, No. 21.

@article{c1f4fb741df849c49c841a457cd8a391,

title = "Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes",

author = "L Pleyer and S Burgstaller and R Stauder and M Girschikofsky and W Linkesch and M Pfeilstocker and EM Autzinger and C Tinchon and T Sliwa and A Lang and WR Sperr and D Geissler and P Krippl and D Voskova and DH Rossmann and K Schlick and J Thaler and B Halter and S Machherndl-Spandl and G Theiler and P Valent and O Eckmullner and Richard Greil",

year = "2014",

language = "English",

volume = "124",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

number = "21",

note = "56th Annual Meeting of the American-Society-of-Hematology ; Conference date: 06-12-2014 Through 09-12-2014",

}

Pleyer, L, Burgstaller, S, Stauder, R, Girschikofsky, M, Linkesch, W, Pfeilstocker, M, Autzinger, EM, Tinchon, C, Sliwa, T, Lang, A, Sperr, WR, Geissler, D, Krippl, P, Voskova, D, Rossmann, DH, Schlick, K, Thaler, J, Halter, B, Machherndl-Spandl, S, Theiler, G, Valent, P, Eckmullner, O & Greil, R 2014, 'Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes', BLOOD , vol. 124, no. 21.

Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. / Pleyer, L; Burgstaller, S; Stauder, R et al.
In: BLOOD , Vol. 124, No. 21, 2014.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes

AU - Pleyer, L

AU - Burgstaller, S

AU - Stauder, R

AU - Girschikofsky, M

AU - Linkesch, W

AU - Pfeilstocker, M

AU - Autzinger, EM

AU - Tinchon, C

AU - Sliwa, T

AU - Lang, A

AU - Sperr, WR

AU - Geissler, D

AU - Krippl, P

AU - Voskova, D

AU - Rossmann, DH

AU - Schlick, K

AU - Thaler, J

AU - Halter, B

AU - Machherndl-Spandl, S

AU - Theiler, G

AU - Valent, P

AU - Eckmullner, O

AU - Greil, Richard

PY - 2014

Y1 - 2014

M3 - Abstract (Journal)

SN - 0006-4971

VL - 124

JO - BLOOD

JF - BLOOD

IS - 21

T2 - 56th Annual Meeting of the American-Society-of-Hematology

Y2 - 6 December 2014 through 9 December 2014

ER -

Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Linkesch W, Pfeilstocker M et al. Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. BLOOD . 2014;124(21).